Of interest, the addition of a low dose of DNMT inhibitor can resensitise EZH2 inhibitor-resistant MM cells to EZH2 inhibition [51], suggesting that combination of EZH2 and DNMT inhibitors could be of therapeutic interest. Here, DNMT1 is linked to Miyoshi myopathy.